Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on August 1, 2019, for the month of August 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
| Metric | Value |
|---|---|
| Issued Share Capital (as of July 31, 2019) | 5,381,929,734 Ordinary Shares (25 pence each) |
| Treasury Shares | 393,505,950 Ordinary Shares |
| Total Voting Rights | 4,988,423,784 |
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of the share capital and voting rights as of July 31, 2019.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Voting Rights Denominator: Shareholders should use 4,988,423,784 as the total number of voting rights to determine if they must notify the Company of their interest or changes thereto.
- Treasury Holdings: Approximately 393.5 million shares are held in Treasury and do not carry voting rights.
- Reporting Date: The capital figures are accurate as of July 31, 2019.